More on INO

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+2.2% Growth)
- Ratings (5.6 Score)
- Holders

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (3/18/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Inovio Pharma (NQ:INO)
Delayed: 1.74 +0.06 (3.57%)
Prev. Close $1.68  
Open$1.69 
52 Wk High$11.69 
52 Wk Low$4.50 
Day High$1.77 
Day Low$1.68 
P/E N/A  
EPS$-0.28 
Volume583,053 

Friends, Peers and Foes (?): STRO, ABVX, AN2, CRNX, EXEL (more...)

Mar 6, 2026 04:00 PM Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – INO
Mar 5, 2026 04:56 PM Form 4 INOVIO PHARMACEUTICALS, For: Mar 04 Filed by: Humeau Laurent
Mar 5, 2026 04:55 PM Form 4 INOVIO PHARMACEUTICALS, For: Mar 04 Filed by: Shea Jacqueline Elizabeth
Mar 5, 2026 04:55 PM Form 4 INOVIO PHARMACEUTICALS, For: Mar 04 Filed by: Sumner Michael John
Mar 5, 2026 04:54 PM Form 4 INOVIO PHARMACEUTICALS, For: Mar 04 Filed by: KIES PETER
Mar 5, 2026 04:05 PM INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Mar 5, 2026 12:08 PM DEADLINE ALERT for TCPC, ORCL, PSFE, and INO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Mar 4, 2026 08:52 AM Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
Mar 4, 2026 08:05 AM INOVIO and Akeso partner on glioblastoma combination therapy trial
Mar 4, 2026 08:05 AM INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
View All Articles

Entities mentioned with INO

View All Entities